Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets
Lilly said oral obesity drugs are expanding the market as investors watch demand from patients who want alternatives to injections.
5 Articles
5 Articles
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs - Regional Media News
By Mariam Sunny Sept 14 (Reuters) - Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk with its Wegovy pill. Novo CEO [...]
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
By Mariam Sunny Sept 14 (Reuters) - Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk with its Wegovy pill. Novo CEO Mik...
Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets
Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company’s executive vice president and president of Lilly USA and G
Pharmaceutical company Eli Lilly believes it is gaining market share from competitor Novo in oral obesity treatment in the United States, Reuters reports.
Lilly’s Obesity Access Push via Medicare Bridge Might Change The Case For Investing In Eli Lilly (LLY)
Lilly’s Obesity Access Push via Medicare Bridge Might Change The Case For Investing In Eli Lilly (LLY) Eli Lilly and Company recently presented at Morgan Stanley's Global Healthcare Conference, where executive vice president Ilya Yuffa outlined efforts to expand access to its obesity medicines,…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
